07:00 , Jul 18, 2005 |  BC Week In Review  |  Clinical News

Duragesic fentanyl regulatory update

Johnson & Johnson (JNJ), New Brunswick, N.J.   Product: Duragesic fentanyl   Business: Neurology   JNJ issued a "Dear Healthcare Professional" letter with revisions to the boxed warning/warnings, contraindications, precautions, and dosage and administration sections...
08:00 , Mar 22, 2004 |  BC Week In Review  |  Clinical News

AVI-4557: Phase Ib data

In a U.K. Phase Ib trial in 8 volunteers, AVI-4557 significantly decreased midazolam clearance and significantly increased Cmax (p=0.025 for both measures). Patients received a 10 mg dose of midazolam followed by 5 daily oral...
07:00 , Oct 20, 2003 |  BC Week In Review  |  Clinical News

AVI-4557: Phase I

AVII began a U.K. Phase I study of oral AVI-4557 in 8 healthy male subjects. Subjects will be given midazolam before and after AVI-4557 dosing. AVI BioPharma Inc. (AVII), Portland, Ore.   Product: AVI-4557  ...
08:00 , Feb 24, 2003 |  BC Week In Review  |  Clinical News

AVI-4557 Neugene: Phase I

In a Phase I study of a single intravenous dose of 300 mg AVI-4557 in healthy volunteers, AVI-4557 down-regulated cytochrome P450 3A4, resulting in a reduction in the breakdown of midazolam. AVI BioPharma Inc. (AVII),...
08:00 , Feb 24, 2003 |  BC Week In Review  |  Clinical News

AVI-4557 Neugene: Phase I

In a Phase I study of 5 consecutive daily intravenous injections of 90 mg AVI-4557 in healthy volunteers, AVI-4557 down-regulated cytochrome P450 3A4, resulting in a reduction in the breakdown of midazolam. AVI BioPharma Inc....